Next-Generation Proteasome Inhibition in Multiple Myeloma

TOP - Supplements
Download PDF
Kim Redic, PharmD, BCPS
Beth Faiman, PhD, APRN-BC, AOCN
Editor in Chief

Supported by funding from Onyx Pharmaceuticals, Inc.

*This publication is not sponsored by, endorsed by, or affiliated with the American Society of Hematology in any way.
 
Articles
Related Items
Staying Abreast of New Treatments
Beth Faiman, PhD, APRN-BC, AOCN
Conference Correspondent  published on April 18, 2017 in Hematologic Cancers, Conference Correspondent, ASH
Managing Patients with Multiple Myeloma
Beth Faiman, PhD, APRN-BC, AOCN
Conference Correspondent  published on April 18, 2017 in Hematologic Cancers, Conference Correspondent, ASH
Perceptions of Daratumumab Therapy
Beth Faiman, PhD, APRN-BC, AOCN
Conference Correspondent  published on April 18, 2017 in Hematologic Cancers, Conference Correspondent, ASH
Starting a Patient on Daratumumab
Beth Faiman, PhD, APRN-BC, AOCN
Conference Correspondent  published on April 18, 2017 in Hematologic Cancers, Conference Correspondent, ASH
What Do Patients Ask About Daratumumab?
Beth Faiman, PhD, APRN-BC, AOCN
Conference Correspondent  published on April 18, 2017 in Hematologic Cancers, Conference Correspondent, ASH
Unmet Needs in Patients with Myeloma
Beth Faiman, PhD, APRN-BC, AOCN
Conference Correspondent  published on April 18, 2017 in Hematologic Cancers, Conference Correspondent, ASH
The Challenge of Managing Treatment-Related Toxicites
Beth Faiman, PhD, APRN-BC, AOCN
Conference Correspondent  published on April 18, 2017 in Hematologic Cancers, Conference Correspondent, ASH
Self-Managing Side Effects
Beth Faiman, PhD, APRN-BC, AOCN
Conference Correspondent  published on April 18, 2017 in Hematologic Cancers, Conference Correspondent, ASH
Concerns Over New Multiple Myeloma Therapies
Beth Faiman, PhD, APRN-BC, AOCN
Conference Correspondent  published on April 18, 2017 in Hematologic Cancers, Conference Correspondent, ASH
How Janssen CarePath Helps Patients
Beth Faiman, PhD, APRN-BC, AOCN
Conference Correspondent  published on April 18, 2017 in Hematologic Cancers, Conference Correspondent, ASH
Last modified: September 9, 2019